<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775774</url>
  </required_header>
  <id_info>
    <org_study_id>ARDS MSC 001</org_study_id>
    <secondary_id>1U01HL108713-01</secondary_id>
    <nct_id>NCT01775774</nct_id>
  </id_info>
  <brief_title>Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome</brief_title>
  <acronym>START</acronym>
  <official_title>A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael A. Matthay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic
      Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute
      Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of
      hMSCs in patients with ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the safety of intravenous infusion of
      Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Pre-specified Infusion Associated Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <description>Any of the following occurring within 6 h of mesenchymal stem-cell infusion:
Addition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:
Norepinephrine: 10 μg per min
Phenylephrine: 100 μg per min
Dopamine: 10 μg/kg per min
Epinephrine: 0·1 μg/kg per min
Hypoxaemia requiring an increase in the fraction of inspired oxygen of ≥0·2 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%
New cardiac arrhythmia requiring cardioversion
New ventricular tachycardia, ventricular fi brillation, or asystole
A clinical scenario consistent with transfusion incompatibility or transfusion-related infection
Cardiac arrest or death within 24 h of mesenchymal stem-cell infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Severe Adverse Events (SAEs)</measure>
    <time_frame>Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.</time_frame>
    <description>The number of participants with a severe adverse event during the study was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days at Study Day 28</measure>
    <time_frame>time of initiating unassisted breathing to day 28</time_frame>
    <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Vasopressor Use (Days)</measure>
    <time_frame>28 days</time_frame>
    <description>Days on vasopressor to day 28 after study enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days to Day 28</measure>
    <time_frame>28 days after study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Survival to Day 60</measure>
    <time_frame>60 days after randomization</time_frame>
    <description>The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at Hospital Discharge</measure>
    <time_frame>From study enrollment to Hospital discharge</time_frame>
    <description>The number of patients expired at hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</intervention_name>
    <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.</description>
    <arm_group_label>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for inclusion if they meet all of the below criteria. Criteria
        1-3 must all be present within a 24-hour time period and at the time of enrollment:

        Acute onset (defined below) of:

          1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a
             PaO2/FiO2 ratio &lt; 200 with at least 8 cm H2O positive end-expiratory airway pressure
             (PEEP)

          2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph

          3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

        In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first
        meeting ARDS criteria per the Berlin definition of ARDS.

        Exclusion Criteria:

          1. Age less than 18 years

          2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of
             ARDS

          3. Pregnant or breast-feeding

          4. Prisoner

          5. Presence of any active malignancy (other than non-melanoma skin cancer) that required
             treatment within the last 2 years

          6. Any other irreversible disease or condition for which 6-month mortality is estimated
             to be greater than 50%

          7. Moderate to severe liver failure (Childs-Pugh Score &gt; 12)

          8. Severe chronic respiratory disease with a PaCO2 &gt; 50 mm Hg or the use of home oxygen

          9. Patient, surrogate, or physician not committed to full support (exception: a patient
             will not be excluded if he/she would receive all supportive care except for attempts
             at resuscitation from cardiac arrest).

         10. Major trauma in the prior 5 days

         11. Lung transplant patient

         12. No consent/inability to obtain consent

         13. Moribund patient not expected to survive 24 hours

         14. WHO Class III or IV pulmonary hypertension

         15. Documented deep venous thrombosis or pulmonary embolism within past 3 months

         16. No arterial line/no intent to place an arterial line

         17. No intent/unwillingness to follow lung protective ventilation strategy or fluid
             management protocol

         18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory
             ventilation (HFOV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17.</citation>
    <PMID>25529339</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael A. Matthay</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Acute Lung Injury</keyword>
  <keyword>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This dose-escalation Phase 1 clinical trial with 3 cohorts with 3 subjects/cohort was performed in 7 centers in USA between July 2013 to January 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Human Mesenchymal Stem Cells 1 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
        <group group_id="P2">
          <title>Human Mesenchymal Stem Cells 5 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
        <group group_id="P3">
          <title>Human Mesenchymal Stem Cells 10 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Human Mesenchymal Stem Cells 1 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
        <group group_id="B2">
          <title>Mesenchymal Stem Cells 5 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
        <group group_id="B3">
          <title>Mesenchymal Stem Cells 10 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" lower_limit="29" upper_limit="86"/>
                    <measurement group_id="B2" value="58.3" lower_limit="46" upper_limit="67"/>
                    <measurement group_id="B3" value="48.3" lower_limit="38" upper_limit="55"/>
                    <measurement group_id="B4" value="54.9" lower_limit="29" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APACHE III Score</title>
          <description>Acute Physiology and Chronic Health Evaluation III score, a severity-of-disease classification system. Higher score predicts worse clinical outcome. The scale of APACHE III is 0 - 299, where 0 = best outcome and 299 = worst outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.7" lower_limit="62" upper_limit="111"/>
                    <measurement group_id="B2" value="89.7" lower_limit="64" upper_limit="115"/>
                    <measurement group_id="B3" value="88.3" lower_limit="54" upper_limit="108"/>
                    <measurement group_id="B4" value="89.9" lower_limit="54" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary cause of ARDS</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspiration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-eclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Pre-specified Infusion Associated Adverse Events</title>
        <description>Any of the following occurring within 6 h of mesenchymal stem-cell infusion:
Addition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:
Norepinephrine: 10 μg per min
Phenylephrine: 100 μg per min
Dopamine: 10 μg/kg per min
Epinephrine: 0·1 μg/kg per min
Hypoxaemia requiring an increase in the fraction of inspired oxygen of ≥0·2 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88–95%
New cardiac arrhythmia requiring cardioversion
New ventricular tachycardia, ventricular fi brillation, or asystole
A clinical scenario consistent with transfusion incompatibility or transfusion-related infection
Cardiac arrest or death within 24 h of mesenchymal stem-cell infusion</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pre-specified Infusion Associated Adverse Events</title>
          <description>Any of the following occurring within 6 h of mesenchymal stem-cell infusion:
Addition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:
Norepinephrine: 10 μg per min
Phenylephrine: 100 μg per min
Dopamine: 10 μg/kg per min
Epinephrine: 0·1 μg/kg per min
Hypoxaemia requiring an increase in the fraction of inspired oxygen of ≥0·2 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88–95%
New cardiac arrhythmia requiring cardioversion
New ventricular tachycardia, ventricular fi brillation, or asystole
A clinical scenario consistent with transfusion incompatibility or transfusion-related infection
Cardiac arrest or death within 24 h of mesenchymal stem-cell infusion</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Severe Adverse Events (SAEs)</title>
        <description>The number of participants with a severe adverse event during the study was assessed.</description>
        <time_frame>Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Severe Adverse Events (SAEs)</title>
          <description>The number of participants with a severe adverse event during the study was assessed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Free Days at Study Day 28</title>
        <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
        <time_frame>time of initiating unassisted breathing to day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Free Days at Study Day 28</title>
          <description>Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.</description>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="22" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O3" value="20" lower_limit="12" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Vasopressor Use (Days)</title>
        <description>Days on vasopressor to day 28 after study enrollment</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Vasopressor Use (Days)</title>
          <description>Days on vasopressor to day 28 after study enrollment</description>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Free Days to Day 28</title>
        <time_frame>28 days after study enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days to Day 28</title>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O3" value="18" lower_limit="9" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Survival to Day 60</title>
        <description>The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
        <time_frame>60 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Survival to Day 60</title>
          <description>The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality at Hospital Discharge</title>
        <description>The number of patients expired at hospital discharge.</description>
        <time_frame>From study enrollment to Hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW</title>
            <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality at Hospital Discharge</title>
          <description>The number of patients expired at hospital discharge.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Human Mesenchymal Stem Cells: 1 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.</description>
        </group>
        <group group_id="E2">
          <title>Human Mesenchymal Stem Cells: 5 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.</description>
        </group>
        <group group_id="E3">
          <title>Human Mesenchymal Stem Cells: 10 Million Cells/kg PBW</title>
          <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Multiorgan failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Infarcts of kidneys, spleen and brain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A. Matthay, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-353-1206</phone>
      <email>michael.matthay@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

